Canine Arthritis Market – Drivers
Factors such as high adoption of pets by common people, increasing expenditure by consumers on veterinary care, and increasing number of approvals for veterinary medicines are expected to drive growth of the canine arthritis market. For instance, in March 2016, USFDA approved Galliprant — an animal drug for osteoarthritis in dogs. Galliprant is a prostaglandin E2 (PGE2) EP4 receptor antagonist, a non-cyclooxygenase inhibiting, non-steroidal anti-inflammatory drug (NSAID) and is intended to control pain and inflammation associated with osteoarthritis in dogs. The application for Galliprant was sponsored by Aratana Therapeutics.
Furthermore, increasing initiatives by professional business services to offer support for pet care is expected to propel the market growth. For instance, in January 2019, the International Boarding & Pet Services Association (IBPSA) appointed one Chief Operating Officer along with three new advisory boards to bring an additional and invaluable experiences of pet care business to IBPSA and its members.
However, side effects associated with canine arthritis treatments are expected to hamper growth of the canine arthritis market.
Canine Arthritis Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients